Bone Metastasis in Prostate Cancer: Bone Scan Versus PET Imaging

Area of Science:

• Oncology
• Radiology
• Nuclear Medicine

Background:

• Prostate cancer bone metastasis significantly impacts patient morbidity and mortality.
• Early detection and treatment of bone metastases are critical for improving survival and quality of life.
• Conventional imaging methods like CT, MRI, and bone scintigraphy have limitations, including high false-positive rates.

Purpose of the Study:

• To provide an overview of molecular imaging techniques for detecting prostate cancer bone metastasis.
• To compare the advantages and limitations of SPECT, SPECT/CT, and PET imaging with various radiopharmaceuticals.
• To highlight advancements in hybrid scanners, artificial intelligence (AI), and radiomics for enhanced detection.

Main Methods:

• Review of SPECT and SPECT/CT bone scintigraphy.
• Evaluation of Positron Emission Tomography (PET)/CT and PET/MRI using different radiotracers.
• Exploration of AI and radiomics in molecular imaging for prostate cancer metastasis.
• Discussion of radiotracers targeting cell division, cancer proteins, and bone-seeking agents.

Main Results:

• PET/CT and PET/MRI show promise in overcoming limitations of standard imaging for bone metastasis detection.
• Radiotracers labeled with isotopes like fluorine-18 and gallium-68 offer reduced radiation dose and preserved biological properties.
• AI and radiomics integration demonstrates potential for improved accuracy, reduced variability, and time savings in interpretation.

Conclusions:

• Molecular imaging, particularly PET-based techniques, offers superior alternatives for identifying prostate cancer bone metastasis.
• Hybrid imaging scanners combined with AI and radiomics represent the future of accurate and efficient detection.
• Continued development of novel radiotracers and imaging analysis tools is essential for optimizing patient management.